AIG
CCCC icon

American International Group’s C4 Therapeutics CCCC Stock Holding History

American International Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-20,302
Closed -$63.7K – 3094
2023
Q1 		$63.7K Buy
20,302
+405
+2% +$2.38K ﹤0.01% 2643
2022
Q4 		$117K Sell
19,897
-73
-0.4% -$605 ﹤0.01% 2432
2022
Q3 		$175K Buy
19,970
+282
+1% +$2.93K ﹤0.01% 2235
2022
Q2 		$148K Buy
19,688
+507
+3% +$4.46K ﹤0.01% 2369
2022
Q1 		$465K Sell
19,181
-1,351
-7% -$32.8K ﹤0.01% 1760
2021
Q4 		$661K Sell
20,532
-614
-3% -$24.3K ﹤0.01% 1642
2021
Q3 		$945K Buy
21,146
+1,849
+10% +$79.2K 0.01% 1471
2021
Q2 		$730 Buy
19,297
+13,077
+210% +$468K ﹤0.01% 1697
2021
Q1 		$230 Buy
6,220
+16
+0.3% +$636 ﹤0.01% 2294
2020
Q4 		$206 Buy
+6,204
New +$180K ﹤0.01% 2273

Other funds holding CCCC

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

American International Group's CCCC Position: Q2 2023 in Review

American International Group sold out of C4 Therapeutics (CCCC) in Q2 2023, closing a stake of 20,302 shares — an estimated $63.7K sold.

American International Group first reported a position in CCCC in Q4 2020 and held it in 10 quarters. The position peaked at $945K in Q3 2021. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

  • American International Group reported no remaining C4 Therapeutics position as of Q2 2023 after selling out during the quarter.
  • American International Group sold 20,302 C4 Therapeutics shares in Q2 2023, an estimated $63.7K.
  • American International Group first reported a position in C4 Therapeutics in Q4 2020 and held it in 10 quarters.
  • American International Group's C4 Therapeutics position peaked at $945K in Q3 2021.
  • 100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on American International Group's 13F filing for Q2 2023, filed 4 Aug 2023.